Opportunity Information: Apply for TI 16 014
Apply for TI 16 014
- The HHS-SAMHS in the health sector is offering a public funding opportunity titled "Targeted Capacity Expansion: Medication Assisted Treatment - Prescription Drug and Opioid Addiction (MAT-PDOA) grants" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.243.
- This funding opportunity was created on Mar 29, 2016 and posted on Mar 29, 2016.
- Applicants must submit their applications by May 31, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
- The number of recipients for this funding is limited to 11 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Targeted Capacity Expansion: Medication Assisted Treatment - Prescription Drug and Opioid Addiction (MAT-PDOA) grant is a SAMHSA (HHS) discretionary services grant designed to quickly expand and strengthen access to medication-assisted treatment for people with opioid use disorder who are seeking or already receiving MAT. The program is aimed at improving both the availability of evidence-based medications and the surrounding clinical and recovery supports that help people start treatment, stay engaged, and reduce opioid misuse. Because it is a services grant, SAMHSA expects awardees to move into direct service delivery rapidly, with treatment services beginning no later than the fourth month of the project.
A defining feature of this opportunity is its targeted focus on states experiencing the greatest burden from heroin and opioid treatment needs. SAMHSA uses its Treatment Episode Data Set (TEDS) from 2007 through 2013 to identify the states with the highest per-capita rates of primary treatment admissions for heroin and opioids, and it gives priority to states showing the sharpest increases over that period. In practice, this means funding is directed where the data show the opioid crisis has produced the most severe treatment demand and where scaling MAT capacity is likely to have the greatest near-term impact.
The grant emphasizes four core outcomes that applicants are expected to drive and measure. First, programs should increase the number of admissions for MAT, reflecting expanded capacity and improved access to these medications. Second, programs should increase the number of clients receiving integrated care or treatment, meaning MAT is delivered as part of a coordinated package rather than as a standalone medication service. Third, programs should demonstrate a decrease in illicit opioid use at a six-month follow-up. Fourth, programs should show a decrease in non-prescribed use of prescription opioids at the same six-month follow-up point. These outcomes collectively reflect SAMHSAs intent to fund programs that not only initiate treatment, but also improve engagement, retention, and real-world reductions in opioid misuse over time.
In this funding announcement, integrated care or treatment is defined broadly as organized delivery and/or coordination of multiple service types for patients with complex needs. It includes medical care and the use of FDA-approved medications for opioid use disorder, specifically buprenorphine, methadone, and naltrexone, along with behavioral health treatment, social services, peer supports, and other recovery support services. The point of the integrated approach is to improve overall health outcomes by addressing the intertwined medical, behavioral, and social factors that influence substance use, recovery stability, and quality of life.
The FOA also spells out what counts as medication-assisted treatment under this program. MAT includes FDA-approved opioid agonist medications such as methadone and buprenorphine (including combination buprenorphine/naloxone products and buprenorphine mono-products) used for maintenance treatment, as well as opioid antagonist therapy with naltrexone (including extended-release and oral forms). Importantly, MAT under this grant is not limited to prescribing or dispensing medication. It must be paired with behavioral therapies to help prevent relapse and should include screening, assessment (including evaluating severity, physical dependence, and appropriateness for MAT), and case management. The program expects MAT to be delivered alongside comprehensive substance use disorder treatment such as counseling and other behavioral therapies, and it recognizes that some clients may also need pharmacotherapy for co-occurring alcohol use disorder. Across all of these components, SAMHSA stresses that services should be clinically driven, person-centered, and individualized rather than one-size-fits-all.
From a policy and systems perspective, MAT-PDOA supports SAMHSAs Strategic Initiative on Health Care and Health Systems Integration. That framing signals that SAMHSA is not only looking for more treatment slots, but also for programs that connect substance use disorder treatment with broader healthcare delivery and coordinated support systems. In addition, the FOA explicitly highlights the need to address behavioral health disparities. Applicants are encouraged to implement strategies that reduce differences in access, service use, and outcomes among populations that have historically faced barriers to care, including racial and ethnic minority groups as well as sexual and gender minority populations. This makes equity-focused outreach, engagement, and retention strategies a central expectation rather than an optional add-on.
Administratively, this opportunity (Funding Opportunity Number TI 16 014; CFDA 93.243) was posted March 29, 2016, with a closing date of May 31, 2016. The award ceiling listed is $1,000,000, and SAMHSA anticipated making 11 awards. The eligibility category in the listing is noted as "Others (see text field entitled Additional Information on Eligibility for clarification)," indicating that the detailed eligibility rules were provided in the full FOA rather than fully captured in the brief synopsis.
MAT-PDOA Grant (SAMHSA) FAQs
What is the MAT-PDOA grant?
The Targeted Capacity Expansion: Medication Assisted Treatment - Prescription Drug and Opioid Addiction (MAT-PDOA) grant is a SAMHSA (HHS) discretionary services grant intended to quickly expand and strengthen access to medication-assisted treatment (MAT) for people with opioid use disorder who are seeking MAT or are already receiving it.
What is the main purpose of this funding opportunity?
The purpose is to improve access to evidence-based medications for opioid use disorder and to strengthen the clinical and recovery supports around MAT so that people can start treatment, stay engaged, and reduce opioid misuse over time.
Is this a planning grant or a direct services grant?
This is a services grant. SAMHSA expects awardees to move into direct service delivery rapidly.
How quickly do funded programs need to start providing treatment services?
Treatment services are expected to begin no later than the fourth month of the project.
Who is the grant designed to serve?
The grant is designed to serve people with opioid use disorder who are seeking medication-assisted treatment or who are already receiving MAT.
What makes this opportunity "targeted"?
A defining feature is its targeted focus on states experiencing the greatest burden from heroin and opioid treatment needs. SAMHSA directs priority based on states with high per-capita rates of primary treatment admissions for heroin and opioids and states showing sharp increases in those rates over time.
How does SAMHSA determine which states have the greatest burden?
SAMHSA uses the Treatment Episode Data Set (TEDS) for the years 2007 through 2013 to identify states with the highest per-capita rates of primary treatment admissions for heroin and opioids, and it prioritizes states with the sharpest increases during that period.
What outcomes are applicants expected to drive and measure?
The FOA emphasizes four core outcomes: (1) increased number of admissions for MAT, (2) increased number of clients receiving integrated care or treatment, (3) decreased illicit opioid use at a six-month follow-up, and (4) decreased non-prescribed use of prescription opioids at a six-month follow-up.
What does "increase the number of admissions for MAT" mean in this program?
It refers to expanding capacity and improving access so more people can be admitted into MAT services.
What does SAMHSA mean by "integrated care or treatment" in this FOA?
Integrated care or treatment is defined broadly as the organized delivery and/or coordination of multiple service types for patients with complex needs, rather than providing MAT as a standalone medication service.
What types of services can be part of integrated care or treatment?
Integrated care can include medical care and FDA-approved medications for opioid use disorder, behavioral health treatment, social services, peer supports, and other recovery support services, coordinated to address medical, behavioral, and social factors that affect recovery and quality of life.
Which FDA-approved medications for opioid use disorder are specifically included?
The FOA identifies buprenorphine, methadone, and naltrexone as FDA-approved medications for opioid use disorder included in the integrated approach.
What counts as medication-assisted treatment (MAT) under this grant?
MAT includes FDA-approved opioid agonist medications such as methadone and buprenorphine used for maintenance treatment, as well as opioid antagonist therapy with naltrexone.
Does the FOA specify forms or products of these medications?
Yes. For buprenorphine, it includes combination buprenorphine/naloxone products and buprenorphine mono-products. For naltrexone, it includes extended-release and oral forms.
Is MAT limited to prescribing or dispensing medication in this program?
No. MAT under this grant is not limited to prescribing or dispensing medication. It must be paired with behavioral therapies to help prevent relapse and include other clinical components described in the FOA.
What clinical components does the FOA expect to accompany MAT?
The FOA expects screening and assessment (including evaluating severity, physical dependence, and appropriateness for MAT), case management, and comprehensive substance use disorder treatment such as counseling and other behavioral therapies.
Does the FOA mention services for co-occurring alcohol use disorder?
Yes. The FOA recognizes that some clients may also need pharmacotherapy for co-occurring alcohol use disorder.
What approach does SAMHSA emphasize for delivering services?
SAMHSA emphasizes that services should be clinically driven, person-centered, and individualized rather than one-size-fits-all.
How does this grant relate to broader SAMHSA priorities?
MAT-PDOA supports SAMHSA's Strategic Initiative on Health Care and Health Systems Integration, signaling an expectation that programs connect substance use disorder treatment with broader healthcare delivery and coordinated support systems.
Does the FOA address behavioral health disparities?
Yes. The FOA explicitly highlights the need to address behavioral health disparities and encourages strategies that reduce differences in access, service use, and outcomes among populations that have historically faced barriers to care.
Which populations are specifically mentioned in relation to disparities?
The FOA mentions racial and ethnic minority groups as well as sexual and gender minority populations.
What is the expectation regarding equity-focused strategies?
The FOA frames equity-focused outreach, engagement, and retention strategies as a central expectation rather than an optional add-on.
What is the Funding Opportunity Number and CFDA number for this grant?
The Funding Opportunity Number is TI 16 014, and the CFDA number is 93.243.
When was this funding opportunity posted and when did it close?
It was posted on March 29, 2016, and the closing date was May 31, 2016.
What is the maximum award amount (award ceiling)?
The award ceiling listed is $1,000,000.
How many awards did SAMHSA anticipate making?
SAMHSA anticipated making 11 awards.
Who is eligible to apply?
The eligibility category in the listing is noted as "Others (see text field entitled Additional Information on Eligibility for clarification)," indicating the detailed eligibility rules were provided in the full FOA rather than fully captured in the synopsis.
Where would applicants find the detailed eligibility requirements?
Based on the listing, the detailed eligibility requirements would be in the full FOA (not fully included in the brief synopsis provided).
What follow-up timeframe is specified for measuring opioid use outcomes?
The FOA specifies measuring decreases in illicit opioid use and decreases in non-prescribed use of prescription opioids at a six-month follow-up.
Browse more opportunities from the same category: Health
Next opportunity: Prevention Innovation Program III (PIP) (R01)
Previous opportunity: Urban Waters Learning Network
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for TI 16 014
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (TI 16 014) also looked into and applied for these:
| Funding Opportunity |
|---|
| Prevention Innovation Program III (PIP) (R01) Apply for RFA AI 16 025 Funding Number: RFA AI 16 025 Agency: HHS-NIH11 Category: Health Funding Amount: $400,000 |
| National Implementation and Dissemination for Chronic Disease Prevention Apply for CDC RFA DP14 141803CONT16 Funding Number: CDC RFA DP14 141803CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Strategic Prevention Framework for Prescription Drugs (SPF Rx) Apply for SP 16 006 Funding Number: SP 16 006 Agency: HHS-SAMHS Category: Health Funding Amount: $371,616 |
| Grants to Prevent Prescription Drug/Opioid Overdose-Related Deaths (PDO) Apply for SP 16 005 Funding Number: SP 16 005 Agency: HHS-SAMHS Category: Health Funding Amount: $11,000,000 |
| Partnerships for Countermeasures against Select Pathogens (R01) Apply for RFA AI 16 034 Funding Number: RFA AI 16 034 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| HPV Roundtable: Creating a National Network of Partners to Promote Cancer Prevention through Human Papillomavirus Vaccination- Financed in Part by 2016 Prevention and Public Health Funds Apply for CDC RFA IP16 1602PPHF16 Funding Number: CDC RFA IP16 1602PPHF16 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: $500,000 |
| New Technologies for the Glycosciences (R41/R42) Apply for PA 16 158 Funding Number: PA 16 158 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Cooperative Agreements for Tribal Behavioral Health Apply for SM 16 010 Funding Number: SM 16 010 Agency: HHS-SAMHS Category: Health Funding Amount: $200,000 |
| New Technologies for the Glycosciences (R43/R44) Apply for PA 16 157 Funding Number: PA 16 157 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Adult Maturational Changes and Dysfunctions in Emotion Regulation (R21) Apply for RFA MH 17 400 Funding Number: RFA MH 17 400 Agency: HHS-NIH11 Category: Health Funding Amount: $200,000 |
| Dental Faculty Development and Loan Repayment Program Apply for HRSA 16 182 Funding Number: HRSA 16 182 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Advancing National Public Health Institutes Globally Apply for CDC RFA GH14 141903CONT16 Funding Number: CDC RFA GH14 141903CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Support for Public Health Drinking Water Programs to Improve Efficiency & Effectiveness for Controlling Drinking Water Exposures Apply for CDC RFA EH15 150702CONT16 Funding Number: CDC RFA EH15 150702CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Tribal Public Health Capacity Building and Quality Improvement Apply for CDC RFA OT13 130304CONT16 Funding Number: CDC RFA OT13 130304CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| NIH Director's Transformative Research Awards (R01) Apply for RFA RM 16 007 Funding Number: RFA RM 16 007 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| NIH Director's New Innovator Award Program (DP2) Apply for RFA RM 16 004 Funding Number: RFA RM 16 004 Agency: HHS-NIH11 Category: Health Funding Amount: $1,500,000 |
| NIH Pioneer Award Program (DP1) Apply for RFA RM 16 005 Funding Number: RFA RM 16 005 Agency: HHS-NIH11 Category: Health Funding Amount: $700,000 |
| Comprehensive Health Services Delivery (CHSD) Apply for RFA 621 16 000012 Funding Number: RFA 621 16 000012 Agency: USAID-TAN Category: Health Funding Amount: $325,211,110 |
| Capacity building for ecological surveillance of viral hemorrhagic fevers in Sierra Leone Apply for CDC RFA CK16 1605 Funding Number: CDC RFA CK16 1605 Agency: HHS-CDC-NCEZID Category: Health Funding Amount: Case Dependent |
| Program Supplements for Violence Intervention to Enhance Lives (Short Title: VITEL) Apply for TI 16 010 Funding Number: TI 16 010 Agency: HHS-SAMHS Category: Health Funding Amount: $70,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "TI 16 014", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.